It's all about revenue from here. Fda approval doesn't guarantee this. Look at Nanosonics, over 10 years they continually built revenue, stashing cash each year. They went from perhaps 60m mcap when I was in and are 1.7bn now. 27 bagger over 10 years. They're quite niche though and not SAAS based so CDX can go much faster... contract will make this grow from here. Imo cdx can be multiples more than NAN. More patience needed from here.
It's all about revenue from here. Fda approval doesn't guarantee...
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
